Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types.

JAAD Int · 2023 · PMC9661502 · PMID 36387062

Europe PMC DOI

hedged sentences

0.0510

closest p · 1.0× alpha

0.0510

boldest claim

The sentences

borderline significantP = .051so close (0.05 < p ≤ 0.1)

In DSTs treated with methotrexate and ciclosporin, EASI showed significant improvements for methotrexate (Δ5.7; P = .048) and borderline significant improvements were found for DLQI (Δ4.9; P = .051) for methotrexate, and EASI for ciclosporin (Δ12.9; P = .054).

also in 11,409 other papers

did not reach statistical significanceno p-value reported

We found that EASI scores improved in both DST and LST when treated with dupilumab, methotrexate, and ciclosporin, although this change did not reach statistical significance in DST ciclosporin patients, probably related to the small sample size.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.